Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Up 38.2% in December

Avalo Therapeutics, Inc. (NASDAQ:AVTX) was the recipient of a large growth in short interest in December. As of December 31st, there was short interest totaling 2,568,740 shares, a growth of 38.2% from the December 15th total of 1,858,418 shares. Based on an average trading volume of 339,981 shares, the days-to-cover ratio is currently 7.6 days. Currently, 13.9% of the shares of the stock are short sold. Currently, 13.9% of the shares of the stock are short sold. Based on an average trading volume of 339,981 shares, the days-to-cover ratio is currently 7.6 days.

Analyst Upgrades and Downgrades

AVTX has been the topic of several research reports. HC Wainwright reiterated a “buy” rating and issued a $25.00 price target on shares of Avalo Therapeutics in a research report on Thursday. BTIG Research reiterated a “buy” rating and set a $40.00 target price on shares of Avalo Therapeutics in a report on Monday, September 29th. Mizuho raised Avalo Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Avalo Therapeutics in a research report on Friday, January 9th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Avalo Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $32.71.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of AVTX. BIT Capital GmbH purchased a new stake in Avalo Therapeutics during the third quarter worth approximately $25,000. PFS Partners LLC raised its stake in shares of Avalo Therapeutics by 100.0% in the 4th quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock valued at $36,000 after acquiring an additional 1,000 shares during the period. Quadrature Capital Ltd acquired a new position in shares of Avalo Therapeutics during the 2nd quarter valued at $55,000. Boothbay Fund Management LLC purchased a new stake in Avalo Therapeutics during the 2nd quarter worth $56,000. Finally, Dimensional Fund Advisors LP acquired a new stake in Avalo Therapeutics in the 3rd quarter valued at $143,000. 87.06% of the stock is currently owned by hedge funds and other institutional investors.

Avalo Therapeutics Stock Performance

Shares of NASDAQ AVTX opened at $15.06 on Monday. The firm has a market cap of $278.76 million, a P/E ratio of -2.81 and a beta of 0.84. Avalo Therapeutics has a 1 year low of $3.39 and a 1 year high of $20.72. The firm’s 50 day moving average price is $17.59 and its 200 day moving average price is $13.18.

Avalo Therapeutics (NASDAQ:AVTX) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($2.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.52). As a group, equities analysts predict that Avalo Therapeutics will post -19.07 EPS for the current year.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.